Abstract
Breast cancer is the most common female malignancy worldwide, however its molecular pathogenesis still needs in-depth investigation. Here we first revealed that the olfactory receptor family 2, subfamily T, member 6 (OR2T6) was significantly over-expressed in breast cancer tissues compared with normal breast tissues. OR2T6 expression was tightly correlated with higher TNM staging, positive lymph node metastasis, and associated with poorer patients' overall and disease-free survival. And OR2T6 enhanced the proliferation, invasion, and migration ability of breast cancer cell lines in vitro (MCF-7 and MDA-MD-231). Mechanically, it promoted the expression of mesenchymal markers (Vimentin, N-cadherin, and β-catenin) while inhibited E-cadherin expression, suggesting that OR2T6 played a key role in the regulation of epithelial-mesenchymal transition (EMT) process. Moreover, the human gene expression microarray clarified that MAPK/ERK pathway could be initiated by OR2T6 at mRNA level, which was further confirmed at protein level by western blot analysis. Thus, we concluded that OR2T6, as a novel oncogene, contributed to the progression of breast carcinoma by the initiation of EMT and MAPK/ERK pathway.
Introduction
Breast cancer remains a leading cause of mortality among women, primarily driven by metastasis—the spread of cancer cells to distant organs. Despite advancements in treatment, the molecular mechanisms underlying breast cancer progression are not fully understood. Recent research has highlighted the "ectopic" expression of olfactory receptors (ORs), members of the G protein-coupled receptor (GPCR) family, in non-olfactory tissues. Some ORs appear to be co-opted by cancer cells to facilitate growth and invasion. This study investigates the role of OR2T6 in breast cancer, a connection previously unexplored.
Methods and Materials
The researchers utilized a comprehensive approach to evaluate OR2T6's role:
- Clinical Cohort: 102 breast cancer and 60 normal breast tissue samples from Qilu Hospital, Shandong University, were analyzed using Immunohistochemistry (IHC) and qPCR.
- Bioinformatics: Genomic alterations were analyzed via cBioPortal (covering over 8,000 cases), and public datasets (GSE72307) were used for initial gene identification.
- Cellular Models: MCF-7 and MDA-MB-231 cell lines were used for gain-of-function (overexpression) and loss-of-function (siRNA knockdown) experiments.
- Functional and Mechanistic Assays: Proliferation (EdU), apoptosis (flow cytometry), and migration/invasion (Transwell) assays were performed. Signaling pathways were mapped using human gene expression microarrays (GSE108006) and Western blotting.
Key Results
The study identified OR2T6 as a significant driver of malignancy. IHC analysis revealed that OR2T6 protein was present in 27.45% of breast cancer tissues but entirely absent in normal breast duct epithelium.
Functionally, OR2T6 overexpression significantly boosted cell proliferation and reduced apoptosis in MCF-7 cells (from 29.0% to 16.5%). Conversely, silencing OR2T6 tripled the rate of cell death. Crucially, OR2T6 was found to initiate the Epithelial-Mesenchymal Transition (EMT), a process where stationary epithelial cells gain migratory properties. This was evidenced by increased mesenchymal markers (Vimentin, N-cadherin, β-catenin) and decreased E-cadherin.
Clinical correlation showed that high OR2T6 levels are linked to higher TNM staging and lymph node metastasis. Patients with OR2T6-positive tumors had a significantly shorter overall survival (mean 97 months) compared to OR2T6-negative patients (mean 124 months).
Discussion
The discovery of OR2T6 as an oncogene suggests that olfactory receptors may serve as critical sensors in the tumor microenvironment. Mechanistically, the study links OR2T6 to the activation of the MAPK/ERK pathway, likely through GPCR-mediated calcium influx and subsequent Ras activation.
While these findings are promising, limitations remain. The specific ligand that activates OR2T6 in breast tissue is unknown. Additionally, while the clinical data is compelling, the study's reliance on in vitro models necessitates future in vivo validation using animal xenografts. Larger patient cohorts will also be required to establish OR2T6 as a standard clinical biomarker.
Conclusion
OR2T6 is a novel oncogene in breast cancer that promotes tumor progression and metastasis by initiating EMT and activating the MAPK/ERK signaling pathway. Its expression serves as a significant prognostic indicator for poor patient survival.
Summary updated